Aortic, Quality of Life and Stenosis

Sarcopenia and aortic valve disease

Heart BMJ

JULY 10, 2024

Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aortic valve replacement (TAVR).

Aortic valve

Aortic valve Aortic Quality of Life TAVR

Cardiawave is Presenting the 30-day Follow-up Results from its “Valvosoft Pivotal Study” on the Teatment of Severe Symptomatic Aortic Valve Stenosis at ACC24

DAIC

APRIL 5, 2024

Presentation title: QUALITY OF LIFE ASSESSMENT AT 30-DAYS FOLLOW-UP OF THE VALVOSOFT PIVOTAL STUDY ON SEVERE AORTIC VALVE STENOSE PATIENTS" (control number 16930) Time and date: April 8, 2024 - 9:32 a.m.–9:42 A summary of the poster session will be published on the Journal of the American College of Cardiology’s website.

Aortic valve

Aortic valve Stenosis Aortic Quality of Life

Impact of cardiac rehabilitation on pre- and post-operative transcatheter aortic valve replacement prognoses

Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

Transcatheter aortic valve replacement (TAVR) is a relatively new treatment method for aortic stenosis (AS) and has been demonstrated to be suitable for patients with varying risk levels.

Aortic valve

Aortic valve Cardiac Rehabilitation Aortic TAVR

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Transcatheter aortic valve replacement in heart failure

European Journal of Heart Failure

JANUARY 31, 2024

ABSTRACT Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The use of transcatheter aortic valve replacement (TAVR) has become the preferred therapy for most patients with AS and concomitant HF.

Aortic valve

Aortic valve Heart Failure Aortic TAVR

Health Care Cost and Resource Utilization After Aortic Valve Replacement According to the Extent of Cardiac Damage

Circulation: Cardiovascular Interventions

APRIL 7, 2025

BACKGROUND:The extent of cardiac damage has been shown to be associated with increased mortality, repeat hospitalization, and decreased quality of life after aortic valve replacement (AVR).

Aortic valve

Aortic valve Aortic Heart Failure Quality of Life

What Is TAVR? A Closer Look at Transcatheter Aortic Valve Replacement

AMS Cardiology

APRIL 16, 2024

If you’ve been diagnosed with aortic stenosis, you might have come across the term TAVR. our blog aims to clearly outline this procedure and how it can significantly improve your quality of life. In aortic stenosis, the valve leaflets stiffen and narrow, restricting blood flow. The post What Is TAVR?

Aortic valve

Aortic valve TAVR Aortic Open-Heart Surgery

Prognostic implications of pulmonary vascular resistance in transcatheter aortic valve implantation

Heart BMJ

DECEMBER 15, 2023

It is a serious condition that can significantly impair quality of life and lead to fatal cardiovascular complications if left unmanaged. Transcatheter aortic valve implantation (TAVI) is a minimally invasive surgical procedure that has revolutionised the treatment of severe aortic stenosis (AS).

Aortic valve

Aortic valve Pulmonary Aortic Quality of Life

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

FEBRUARY 15, 2024

Tricuspid regurgitation can put added strain on the heart and lead to other cardiovascular issues, which can significantly worsen a person's quality of life, but historically there have been few treatment options," said Lars Søndergaard , M.D.,

Tricuspid

Tricuspid Heart Valves Quality of Life Bicuspid/Mitral

Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

DAIC

MARCH 28, 2024

milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. Circulation.

TAVR

TAVR Stenosis Aortic Aortic valve

AHA Raises Awareness on HVD

DAIC

MARCH 4, 2025

The Most Common Form of HVD One of the most prevalent and serious forms of heart valve disease is aortic stenosis (AS), a condition characterized by the narrowing of the aortic valve opening, which affects approximately 5% of adults over 65a number expected to more than double by 2050.

Heart Valves

Heart Valves Aortic valve Aortic Stenosis

Impact of aortic valve replacement in symptomatic low-risk patients with less than severe aortic stenosis

Open Heart

MAY 12, 2023

Objective To evaluate whether transcatheter or surgical aortic valve replacement (TAVR or SAVR) affects clinical and haemodynamic outcomes in symptomatic patients with moderately-severe aortic stenosis (AS). <aortic valve area (AVA)<1.5 <aortic valve area (AVA)<1.5 cm 2 , 3.0<peak cm 2 , 3.0<peak

Aortic valve

Aortic valve Aortic Stenosis TAVR

Intervention for critical aortic stenosis in Hutchinson-Gilford progeria syndrome

Frontiers in Cardiovascular Medicine

APRIL 24, 2024

With this longer lifespan, calcific aortic stenosis (AS) was identified as an emerging critical risk factor for cardiac death in older patients. Modified transcatheter aortic valve replacement (TAVR) and left ventricular Apico-Aortic Conduit (AAC) placement were deemed high risk but viable options. years by 4.3

Stenosis

Stenosis Aortic Peripheral Arterial Disease TAVR

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

APRIL 2, 2024

Data from the TRILUMINATE Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one year. are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S

Tricuspid

Tricuspid Heart Valves Quality of Life Open-Heart Surgery

New Technology Promises to Revolutionize Valvular Heart Disease Care

DAIC

APRIL 1, 2024

Earlier detection can extend the quality of life with treatments designed to prevent progression. Cholesterol may cause or exacerbate some types of valvular heart disease, so drug companies are testing statins and PSK9 inhibitors (which lower cholesterol even more than statins) against aortic stenosis.

Technology

Technology Heart Disease Innovation Ultrasound

TAVR Found Non-Inferior to SAVR for Low-Risk Patients

DAIC

APRIL 11, 2024

TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. Future analyses will include additional metrics for assessing clinical superiority as well as quality of life outcomes. SAVR in 1,414 patients who underwent valve replacement procedures at 38 centers in Germany.

TAVR

TAVR Aortic valve Aortic COVID-19

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

TAVR UNLOAD: Preemptive TAVR Not Superior to CASS in Patients With HFrEF and Moderate AS

American College of Cardiology

OCTOBER 28, 2024

Findings from the TAVR UNLOAD trial found preemptive TAVR was not superior to clinical aortic stenosis surveillance (CASS) for the hierarchical occurrence of all-cause death, disabling stroke, disease-related hospitalizations and heart failure equivalents, and change in quality of life among patients with moderate aortic stenosis (AS) and heart failure (..)

TAVR

TAVR Quality of Life Heart Failure Stenosis

Cardiawave Releases Positive Data on Non-Invasive Valvosoft Aortic Valve Therapy

DAIC

NOVEMBER 7, 2024

28, 2024 — Cardiawave SA, developer of Valvosoft Non-Invasive Ultrasound Therapy (NIUT) device for treating severe symptomatic calcific aortic stenosis (CAS), announced that the device met the primary endpoint in its pivotal study and improved or stabilized heart failure symptoms for 80.5 tim.hodson Thu, 11/07/2024 - 10:19 Oct.

Aortic valve

Aortic valve Aortic Stenosis Ultrasound

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC)

Cardiometabolic Health Congress

NOVEMBER 14, 2024

What better way to join the fall festivities than by spotlighting key insights in cardiorenal metabolic medicine, primary prevention, and quality of life improvements shared at this year’s biggest U.S. High Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), aortic stenosis, and all-cause mortality.

CME

CME Obesity Heart Failure Biomarkers

Cardiovascular Update

Sarcopenia and aortic valve disease

Cardiawave is Presenting the 30-day Follow-up Results from its “Valvosoft Pivotal Study” on the Teatment of Severe Symptomatic Aortic Valve Stenosis at ACC24

Impact of cardiac rehabilitation on pre- and post-operative transcatheter aortic valve replacement prognoses

Webinars

Transcatheter aortic valve replacement in heart failure

Health Care Cost and Resource Utilization After Aortic Valve Replacement According to the Extent of Cardiac Damage

What Is TAVR? A Closer Look at Transcatheter Aortic Valve Replacement

Prognostic implications of pulmonary vascular resistance in transcatheter aortic valve implantation

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

AHA Raises Awareness on HVD

Impact of aortic valve replacement in symptomatic low-risk patients with less than severe aortic stenosis

Intervention for critical aortic stenosis in Hutchinson-Gilford progeria syndrome

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

New Technology Promises to Revolutionize Valvular Heart Disease Care

TAVR Found Non-Inferior to SAVR for Low-Risk Patients

Published Research

Published Research

TAVR UNLOAD: Preemptive TAVR Not Superior to CASS in Patients With HFrEF and Moderate AS

Cardiawave Releases Positive Data on Non-Invasive Valvosoft Aortic Valve Therapy

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC)

Stay Connected